The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Market Size Of The Rare Disease Genome Editing Market In 2026 And What Value Is Projected For 2030?
The rare disease genome editing market has seen significant expansion in recent years. Its valuation is anticipated to climb from $1.29 billion in 2025 to $1.51 billion in 2026, showing a compound annual growth rate (CAGR) of 17.8%. The observed growth over the past period is primarily due to advancements in gene editing technologies, a greater understanding of rare genetic mutations, increased funding for genomic research, promising early results from gene therapy trials, and a proliferation of academic research initiatives.
The rare disease genome editing market is projected to experience significant expansion over the upcoming years. This market is anticipated to reach $2.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 17.5%. This projected growth throughout the forecast period stems from several factors, including heightened investment in curative treatments for rare diseases, a growing embrace of precision medicine strategies, the expansion of clinical trials for genome editing, increasing regulatory backing for orphan drugs, and enhanced partnerships between biotechnology firms and healthcare providers. Key trends anticipated during this period involve the increasing uptake of CRISPR-based therapies, a heightened focus on gene editing specifically for monogenic disorders, the wider application of personalized genome editing methods, the expansion of sophisticated editing platforms, and improved integration of genomic data analytics.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28313&type=smp
What Key Drivers Are Influencing The Growth Of The Rare Disease Genome Editing Market?
The future expansion of the rare disease genome editing market is anticipated to be driven by the escalating emphasis on precision medicine. This tailored healthcare methodology, known as precision medicine, leverages an individual’s genetic makeup, environmental factors, and lifestyle choices to deliver more precise and impactful treatments. The heightened attention on precision medicine stems from advancements in genomic sequencing and the identification of biomarkers, which facilitate accurate diagnosis and the development of targeted therapies. The rare disease genome editing market plays a crucial role in advancing precision medicine through its capacity for precise correction of genetic mutations, thereby ensuring more personalized and efficacious treatments. This technology contributes to healthcare progress by tackling the fundamental causes of rare conditions, leading to enhanced patient results and a decreased dependence on managing symptoms alone. As an illustration, in March 2024, Novotech, an Australian biotechnology firm, reported that in 2023, 43% of the 217 oncology therapies sanctioned by the FDA were precision oncology treatments, with 78 of these integrating DNA or NGS-detectable biomarkers. Consequently, the expanding emphasis on precision medicine is a key factor propelling the growth of the rare disease genome editing market.
What Are The Key Segments Of The Rare Disease Genome Editing Market?
The rare disease genome editing market covered in this report is segmented –
1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9, Transcription Activator-Like Effector Nucleases (TALEN), Zinc Finger Nucleases (ZFN), Other Technologies
2) By Disease Type: Monogenic Disorders, Multifactorial Disorders, Chromosomal Disorders
3) By Application: Therapeutics, Research
4) By End User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Hospitals
Subsegments:
1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13, Base Editing, Prime Editing
2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN), Designer Transcription Activator-Like Effector Nucleases (dTALEN), Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases
3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN), Engineered Zinc Finger Nucleases (ZFN), Modular Zinc Finger Nucleases (ZFN)
4) By Other Technologies: Meganucleases, Ribonucleic Acid (RNA)-Guided Nucleases, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases
What Key Trends Are Influencing The Development Of The Rare Disease Genome Editing Market?
Leading firms in the rare disease genome editing market are concentrating on creating sophisticated therapeutic platforms, such as CRISPR-based gene editing technologies, aimed at elevating treatment accuracy, bettering patient results, and tackling genetic ailments that were previously untreatable. These CRISPR-based systems represent novel technologies that facilitate exact alterations to the genome, enabling the correction of genetic flaws or the insertion of therapeutic genes into cellular structures. As an illustration, in December 2023, Vertex Pharmaceuticals Inc., a US-based biopharmaceutical entity, collaborated with CRISPR Therapeutics Inc., a US-based biotechnology research firm, and obtained conditional marketing approval from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). This treatment is prescribed for individuals aged 12 and above suffering from sickle cell disease (SCD) with recurrent vaso-occlusive crises, or transfusion-dependent beta thalassemia (TDT). Casgevy functions by modifying a patient’s hematopoietic stem cells to re-initiate fetal hemoglobin synthesis, thereby diminishing or eradicating disease manifestations and providing a potential functional remedy for these ailments.
Who Are The Leading Companies Operating In The Rare Disease Genome Editing Market?
Major companies operating in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., MeiraGTx Holdings plc
Read the full rare disease genome editing market report here:
https://www.thebusinessresearchcompany.com/report/rare-disease-genome-editing-global-market-report
Which Region Is Expected To Register The Fastest Growth In The Rare Disease Genome Editing Market?
North America was the largest region in the rare disease genome editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genome editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Rare Disease Genome Editing Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28313&type=smp
Browse Through More Reports Similar to the Global Rare Disease Genome Editing Market 2026, By The Business Research Company
Genome Editing Or Genome Engineering Market Report 2026
Crispr Gene Editing Market Report 2026
https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report
Gene Editing Market Report 2026
https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model